| 1. |
- Höglund, Odd
(author)
-
Medical device
- 2018
-
Patent (other academic/artistic)abstract
- A medical device (100) comprises an elongated, flexible band (110) having a front side (112), a rear side (114), a leading end (116) and a trailing end (118), and having perforations (120) and rungs (122) defined therein. A locking case (130, 132) is arranged on the front side (112) of the band (112) and has a channel (150) dimensioned for reception of the band (110). The medical device (100) also comprises a locking member (140, 142, 144) configured to interlock perforations (120) and rungs (122) defined in the band (110). Multiple studs (160, 162) are arranged on the rear side (114) of the band (110).
|
|
| 2. |
- Bidarian-Moniri, Armin
(author)
-
Device for Equalization of the Pressure in the Middle Ear
- 2013
-
Patent (other academic/artistic)abstract
- Device for the equalization of middle ear pressure for non-surgical ventilation of the middle ear for treatment of otitis media with effusion/serous otitis media in infants, children and adults.
|
|
| 3. |
|
|
| 4. |
- Aahlin, Kristofer, et al.
(author)
-
Preparation of 1-(4-(5-amino-6-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-yl)benzoyl)piperazine derivatives as glycogen synthase kinase 3 inhibitors.
- 2011
-
Patent (pop. science, debate, etc.)abstract
- Title compds. I [R1 = H or Me], and their pharmaceutically acceptable salts, are prepd. and disclosed as glycogen synthase kinase 3 (GSK3) inhibitors. Thus, e.g., II was prepd. by cyclization of 3-amino-N-(4-hydroxypyridin-3-yl)pyrazine-2-carboxamide (prepn. given) to get intermediate 3-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-amine, which underwent bromination followed by Suzuki reaction with (4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone. Compds. of the invention were tested for their selective inhibitory activity of GSK3β, e.g., II exhibited Ki value of 2.3 nM. The invention compds. are useful for the treatment of cognitive disorders, diabetes, cancer, etc. [on SciFinder(R)]
|
|
| 5. |
- Almhöjd, Ulrica S., et al.
(author)
-
Preparation for treatment of wounds and sores comprising hypochlorite and amino acids : WO 2014016157
- 2014
-
Patent (other academic/artistic)abstract
- A kit of parts for use in prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis. The kit of parts comprises a first aqueous component comprising one or more amino acids, and a second aqueous component comprising an active halogen compound, wherein the pH of the first component and/or the second component is about 9 to 11.5. There is also provided a treatment preparation prepared from the components and uses thereof in the prevention and/or treatment of sores, wounds, ulcers or the like, or a fistula or otitis.
|
|
| 6. |
|
|
| 7. |
- Andersson, Sören, 1957-, et al.
(author)
-
Chimeric MOMP antigen
- 2014
-
Patent (pop. science, debate, etc.)abstract
- The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.
|
|
| 8. |
- Antonov, D, et al.
(author)
-
HCV inhibiting macrocyclic phenylcarbamates
- 2008
-
Patent (pop. science, debate, etc.)abstract
- Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
|
|
| 9. |
- Arvidsson, Per I., et al.
(author)
-
Preparation of imidazolylpyrimidine derivatives for treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease.
- 2010
-
Patent (pop. science, debate, etc.)abstract
- Title compds. I [R1 = H or F; R2 and R3 independently = H or Me], and their pharmaceutically acceptable salts, are prepd. and disclosed as agents for treatment of glycogen synthase kinase 3 (GSK3) related disorders such as Alzheimer's disease. Thus, e.g., II.HCl was prepd. by reductive amination of 4-bromo-3-fluorobenzaldehyde with (S)-3-methylmorpholine followed by amination with 2-amino-5-fluoro-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidine. Select I were evaluated for GSK3β inhibitory activity, and e.g., II·HCl demonstrated a Ki value of 30 nM. [on SciFinder(R)]
|
|
| 10. |
- Arvidsson, Per, et al.
(author)
-
Preparation of arylimidazopyridine derivatives for use as GSK3 modulators.
- 2008
-
Patent (pop. science, debate, etc.)abstract
- Title compds. I [A = (un)substituted aryl or heteroaryl; Q = halo; R1 = C(O)NR6R7; R2 and R4 independently = H, halo, CN, NO2, alkyl, or haloalkyl; R3 and R5 independently = H, halo, alkyl, or haloalkyl; R6 and R7 = together with the atoms to which they are attached form an (un)substituted heterocyclic ring contg. one or more heteroatoms selected from N, O, or S;], and their pharmaceutically acceptable salts, are prepd. and disclosed as glycogen synthase kinase-3 (GSK3) modulators. Thus, e.g., II•HCl was prepd. by cyclocondensation of 5-bromopyridine-2,3-diamine with terephthalic monomethyl ester followed by chlorination, iodination, sapon., amidation with N-methylpiperazine, and coupling with 4-methoxyphenyl boronic acid. I were evaluated in GSK3β scintillation proximity assays, e.g., II•HCl demonstrated an Ki value of 97 nM. [on SciFinder(R)]
|
|
